You are in: Prescription Medicines > C > CLAVASEPTIN PALATABLE TABLETS 500MG

This product requires a written prescription from your veterinary surgeon. We are only able to dispatch the product upon receipt of the valid and original written prescription in the post.

Size: PK 100
Code: 157855
Sold By: PACK
Manufacturer: Vetoquinol UK Ltd
Availability: Usually shipped in 1 business day, subject to receipt of prescription



Uses - Clavaseptin

In dogs: treatment or adjunctive treatment of periodontal infections caused by bacteria susceptible to amoxicillin in combination with clavulanic acid i.e. Pasteurella spp, Streptococcus spp and Escherichia coli.
In cats: treatment of skin infections (including wounds and abscesses) caused by bacteria susceptible to amoxicillin in combination with clavulanic acid i.e. Pasteurella spp, Staphylococcus spp, Streptococcus spp and Escherichia coli.

Dosage and administration - Clavaseptin

The recommended dose of Clavaseptin Palatable Tablets is 10 mg amoxicillin/2.5mg clavulanic acid/kg twice daily by the oral route in dogs and cats according to the following table.
Bodyweight (kg) 50mg tablets 1 tablet per 4kg bodyweight every 12h 250mg tablets 1 tablet per 20kg body weight every 12h 500mg tablets 1 tablet per 40kg bodyweight every 12h
[1.0-2.0] ½
[2.1-4.0] 1
[4.1-6.0] 1½
[6.1-8.0] 2
[8.1-10] ½
[10.1-20] 1
[20.1-30] 1½
[30.1-40] 2 1
[40.1-60] 1½
[60.1-80] 2
Duration of treatment:
- 7 days for the treatment of periodontal infections in dogs
- 7 to 14 days for the treatment of skin infections in cats (including wounds and abscesses). The clinical status of animals should be re-evaluated after 7 days and the treatment prolonged for a further 7 days if necessary.
To ensure the correct dosage, bodyweight should be determined as accurately as possible to avoid under-dosing.
Administration is made easier by the palatable nature of the tablet.


Contra-indications, warnings, etc
Do not use in case of hypersensitivity to penicillins or other substances of the β-lactam group.
Do not administer to gerbils, guinea pigs, hamsters, rabbits and chinchillas.
Special precautions for use in animals

In animals with impaired liver and kidney function, the use of the product should be subject to a risk/benefit evaluation by the veterinary surgeon and the posology evaluated carefully.
Caution is advised in the use of Clavaseptin in any other small pet (non food-producing) herbivores.
Use of the product should be based on susceptibility testing.
Inappropriate use of the product may increase the prevalence of bacteria resistant to amoxicillin/clavulanic acid. Use of the product should take into account official and local antimicrobial policies.
Adverse reactions (frequency and seriousness)

Vomiting and diarrhoea may be observed. Treatment may be continued depending on the severity of the undesirable effect observed and a benefit/risk evaluation by the veterinary surgeon.
Hypersensitivity reactions (allergic skin reactions, anaphylaxis) may be observed. In these cases, administration should be discontinued and a symptomatic treatment given.
Use during pregnancy and lactation
The safety of the product has not been established during pregnancy and lactation. Laboratory studies in rats have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects. Use the product only accordingly to the benefit/risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction
The bactericidal activity of amoxicillin may be reduced by the simultaneous use of bacteriostatic substances such as macrolides, tetracyclines, sulfonamides and chloramphenicol.
Overdose (symptoms, emergency procedures, antidotes), if necessary
At three times the recommended dose for a period of 28 days, diarrhoea was observed in dogs. In the event of an overdose, symptomatic treatment is advised.

Operator warning
Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.
1. Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.
2. Handle this product with great care to avoid exposure, taking all recommended precautions.
3. If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.
Wash hands after handling the tablets

Pharmaceutical precautions
Shelf-life of the veterinary medicinal product as packaged for sale: Clavaseptin 50 mg Tablets 2 years; Clavaseptin 250 mg and 500 mg tablets 3 years.
Shelf life after first opening the immediate packaging: 12 hours.
Do not store above 25°C. Store in the original package.
Return any halved tablet to the opened strip-pack and use within 12 hours.
Any unused product or waste material should be disposed of in accordance with national requirements.

Legal category

Packaging Quantities
Clavaseptin 50mg Palatable Tablets: 10 and 50 blisters of 10 tablets
Clavaseptin 250mg Palatable Tablets: 10 and 25 blisters of 10 tablets
Clavaseptin 500mg Palatable Tablets: 10 blisters of 10 tablets.

Further information
Amoxicillin is an aminobenzylpenicillin from the β-lactam penicillin family which prevents the bacterial cell wall formation by interfering with the final step of peptidoglycan synthesis.
Clavulanic acid is an irreversible inhibitor of intracellular and extracellular β-lactamases which protects amoxicillin from inactivation by many β-lactamases.

Amoxicillin/clavulanate has a wide range of activity which includes β lactamase producing strains of both Gram-positive and Gram-negative aerobes, facultative anaerobes and obligate anaerobes.
Resistance to β-lactam antibiotics is mainly mediated by β-lactamases which hydrolyze antibiotics such as amoxicillin. It is mostly shown in Pseudomonadaceae (81.25%) and in Enterobacter spp. (55.5%).
After oral administration at the recommended dose in dogs and cats, the absorption of amoxicillin and clavulanic acid is fast. In dogs, the maximum plasma concentration of amoxicillin of 8.5 µg/ml is reached in 1.4 h and the maximum plasma concentration of clavulanic acid of 0.9 µg/ml is reached in 0.9h.
In cats, the maximum plasma concentration of amoxicillin of 6.6 µg/ml is reached in 1.8 h and the maximum plasma concentration of clavulanic acid of 3.7 µg/ml is reached in 0.75h. Elimination is also fast.
After repeated oral administration of the recommended dose in dogs and cats, there is no accumulation of amoxicillin or clavulanic acid and the steady state is reached rapidly after first administration.

Marketing authorisation number
Clavaseptin 50mg Palatable Tablets: Vm 08007/4113.
Clavaseptin 250mg Palatable Tablets: Vm 08007/4114.
Clavaseptin 500mg Palatable Tablets: Vm 08007/4115.

GTIN (Global Trade Item No)
Clavaseptin 50mg 10 x 10
Clavaseptin 50mg 50 x 10
Clavaseptin 250mg 10 x 10
Clavaseptin 250mg 25 x 10
Clavaseptin 500mg

Product Reviews

Be the first to leave a review below

Leave a Review

Your review 
Please note your review will require vetting before publication. Please complete the mandatory fields (*)